MIM
VERV

MetLife Investment Management’s Verve Therapeutics VERV Stock Holding History

MetLife Investment Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,992
Closed -$449K – 2918
2025
Q2 		$449K Sell
39,992
-181
-0.5% -$1.03K ﹤0.01% 1731
2025
Q1 		$184K Hold
40,173
– – ﹤0.01% 2248
2024
Q4 		$227K Hold
40,173
– – ﹤0.01% 2245
2024
Q3 		$194K Hold
40,173
– – ﹤0.01% 2302
2024
Q2 		$196K Buy
40,173
+5,910
+17% +$37.1K ﹤0.01% 2255
2024
Q1 		$455K Buy
34,263
+7,205
+27% +$95.6K ﹤0.01% 1727
2023
Q4 		$377K Hold
27,058
– – ﹤0.01% 1849
2023
Q3 		$359K Hold
27,058
– – ﹤0.01% 1834
2023
Q2 		$507K Buy
27,058
+2,381
+10% +$39.7K ﹤0.01% 1682
2023
Q1 		$356K Hold
24,677
– – ﹤0.01% 1859
2022
Q4 		$478K Hold
24,677
– – ﹤0.01% 1674
2022
Q3 		$848K Buy
24,677
+3,739
+18% +$119K 0.01% 1276
2022
Q2 		$320K Hold
20,938
– – ﹤0.01% 1978
2022
Q1 		$478K Buy
20,938
+15,124
+260% +$432K ﹤0.01% 1797
2021
Q4 		$214K Hold
5,814
– – ﹤0.01% 2012
2021
Q3 		$273K Buy
+5,814
New +$342K ﹤0.01% 1883

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MetLife Investment Management's VERV Position: Q3 2025 in Review

MetLife Investment Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 39,992 shares — an estimated $449K sold.

MetLife Investment Management first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $848K in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • MetLife Investment Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • MetLife Investment Management sold 39,992 Verve Therapeutics shares in Q3 2025, an estimated $449K.
  • MetLife Investment Management first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • MetLife Investment Management's Verve Therapeutics position peaked at $848K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.